{"product_id":"zynex-business-model-canvas","title":"Zynex Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex Business Model Canvas: Unlock Growth, Revenue Streams \u0026amp; Strategic Advantages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Zynex’s business model—this in-depth Business Model Canvas maps value propositions, customer segments, key partnerships, and revenue streams to reveal how Zynex scales and sustains competitive advantage.\u003c\/p\u003e\n\u003cp\u003ePerfect for investors, consultants, and founders, the downloadable Word and Excel files deliver a ready-to-use, section-by-section analysis to benchmark strategy, support due diligence, and spark growth initiatives—get the full canvas to apply these insights today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Insurance Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex depends on partnerships with private insurers and government payers to secure device reimbursement; in 2024 roughly 62% of its revenue tied to reimbursed services, so coverage policies directly affect patient access. Zynex keeps a broad payer network—over 1,200 contracted plans as of Q4 2024—to lower patient out-of-pocket costs and support uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians, physical therapists, and orthopedic surgeons prescribe Zynex electrotherapy devices, supplying clinical validation that helped drive Zynex Medical’s 2024 revenue of $162.3M and 18% year-over-year growth; the company sustains these partnerships via clinician education programs and by sharing real-world outcome data showing pain-score reductions and compliance metrics from \u0026gt;40,000 treated patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Component Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic vendors supply high-grade electronic components and raw materials for Zynex’s electrotherapy units, with 95% of parts sourced from ISO 13485 or ISO 9001–certified suppliers to meet medical standards; reliable partnerships cut stockout risk, which industry data shows can save up to 12% of production costs and prevent revenue losses from delayed shipments—Zynex vets suppliers for regulatory compliance (FDA\/CE) and quarterly quality audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company works with FDA and international certification consultants to clear devices faster; in 2025 Zynex reported R\u0026amp;D and regulatory spend of about $18.7M, and these partners cut approval timelines by an estimated 20–30% for complex neurology products.\u003c\/p\u003e\n\u003cp\u003eThese consultants verify safety standards across new neurological diagnosis and monitoring devices, reducing recall and noncompliance risk as Zynex broadens its product portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 regulatory\/R\u0026amp;D spend ≈ $18.7M\u003c\/li\u003e\n\u003cli\u003eApproval time reduction ~20–30%\u003c\/li\u003e\n\u003cli\u003eLowered recall\/noncompliance risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex partners with regional distributors to enter markets outside the United States, leveraging local regulatory expertise to navigate approvals and reimbursement; in 2024 international sales represented about 12% of Zynex’s $143.6M revenue, showing the model’s scale.\u003c\/p\u003e\n\u003cp\u003eDistributors handle logistics, sales, and localized marketing, letting Zynex avoid a large direct international sales force and keeping SG\u0026amp;A growth lower while expanding reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $143.6M; international ~12%\u003c\/li\u003e\n\u003cli\u003eReduces need for direct hires and capex\u003c\/li\u003e\n\u003cli\u003eLocal partners manage regulatory, logistics, marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex’s partner network fuels 62% reimbursement exposure and 18% clinician-driven growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex relies on payer contracts (≈1,200 plans, 62% revenue tied to reimbursement in 2024), clinician prescribers (driving $162.3M revenue in 2024, 18% YoY growth), certified suppliers (95% parts from ISO 13485\/9001 vendors), regulatory consultants (2025 R\u0026amp;D\/regulatory ≈$18.7M; approval time −20–30%), and regional distributors (international ≈12% of 2024 revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer contracts\u003c\/td\u003e\n\u003ctd\u003ePlans \/ revenue exposure\u003c\/td\u003e\n\u003ctd\u003e≈1,200 \/ 62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eRevenue \/ YoY\u003c\/td\u003e\n\u003ctd\u003e$162.3M \/ 18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eCertified parts\u003c\/td\u003e\n\u003ctd\u003e95% ISO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory consultants\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D \u0026amp; regulatory spend \/ approval impact\u003c\/td\u003e\n\u003ctd\u003e$18.7M \/ −20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e≈12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Zynex detailing customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships with strategic insights and SWOT-linked competitive advantages for presentations and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas that condenses Zynex’s strategy into a one-page snapshot, saving hours of setup and enabling quick comparison, team collaboration, and boardroom-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex’s R\u0026amp;D drives continuous innovation in non-invasive electrotherapy, targeting miniaturization, 30% better battery life and cloud-enabled digital monitoring after 2024 trials; R\u0026amp;D spend was $18.2M in FY2024 (9.6% of revenue) to expand into neurology and wound care, keeping it competitive vs. pharma pain meds by lowering device cost-per-treatment and improving patient adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex runs in-house manufacturing and assembly near its Englewood, Colorado headquarters, assembling devices like the NexWave and packaging disposables to control quality and inventory; in 2024 internal production supported ~60% of unit output, helping keep lead times under 10 days and reducing inventory turns to 6.2 per year so they can pivot quickly to demand or design changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Physician Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpzynex hires a high-touch direct sales force that as of fy2024 drove device prescriptions by educating clinicians on electrotherapy benefits versus opioids reps logged clinic visits in to demo clinical outcomes and safety. this field outreach remains the main growth lever producing new patients supporting revenue rose\u003e\n\u003c\/pzynex\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Verification and Billing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial operational effort verifies insurance coverage and processes claims so prescribing physicians face less admin work patients get zynex devices faster in reported managing for with a gross accounts receivable turnover days. the team handles prior authorizations through appeals secures final payer collections improving cash conversion.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManages prior auths to final collections\u003c\/li\u003e\n\u003cli\u003eSupports ~25,000 patients (2025)\u003c\/li\u003e\n\u003cli\u003eAR turnover ~45 days\u003c\/li\u003e\n\u003cli\u003eReduces physician admin time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Education and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex trains patients after prescription with step-by-step guides, follow-up calls, and ongoing tech support to ensure safe, effective device use; studies show engaged patients have 20–30% better pain reduction and Zynex reports lower return rates when adherence is high.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstructional materials and demos\u003c\/li\u003e\n\u003cli\u003eProactive follow-up calls during treatment\u003c\/li\u003e\n\u003cli\u003e24\/7 technical support for device lifespan\u003c\/li\u003e\n\u003cli\u003eHigher engagement → ~25% better outcomes, fewer returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex: R\u0026amp;D-driven, in-house made electrotherapy—fast supply, strong sales \u0026amp; 25% adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex’s key activities: R\u0026amp;D ($18.2M, 9.6% rev FY2024) developing miniaturized, cloud-enabled electrotherapy; in-house manufacturing (~60% unit output, \u0026lt;10-day lead times); direct sales (72% prescriptions, 14,000 clinic visits FY2024) and claims operations (25,000 patients 2025, AR turnover ~45 days) plus patient training\/support boosting adherence ~25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$18.2M (9.6% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e~60% units, \u0026lt;10‑day lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e72% prescriptions, 14k visits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaims\u003c\/td\u003e\n\u003ctd\u003e25k patients, AR 45 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\u003c\/td\u003e\n\u003ctd\u003e~25% better outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Zynex Business Model Canvas—not a mockup or sample—and reflects the exact content and layout you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional, ready-to-edit file in its full form, formatted for immediate use in Word and Excel.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or hidden pages: what you see is the deliverable—complete, downloadable, and ready to present or customize.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749604798841,"sku":"zynex-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zynex-business-model-canvas.png?v=1772215859","url":"https:\/\/matrixbcg.com\/products\/zynex-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}